Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review

The coronavirus disease 2019 (COVID‐19) pandemic has affected millions of people worldwide resulting in significant morbidity and mortality. Arrhythmias are prevalent and reportedly, the second most common complication. Several mechanistic pathways are proposed to explain the pro‐arrhythmic effects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. A number of treatment approaches have been trialled, each with its inherent unique challenges. This rapid systematic review aimed to examine the current incidence and available treatment of arrhythmias in COVID‐19, as well as barriers to implementation.

[1]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[2]  G. Kay,et al.  Atrial Arrhythmias in COVID-19 Patients , 2020, JACC: Clinical Electrophysiology.

[3]  C. Albert,et al.  Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring , 2020, Journal of the American Heart Association.

[4]  Amit N. Patel,et al.  RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[5]  J. Mourad,et al.  Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection , 2020, Mayo Clinic Proceedings.

[6]  Angelo B. Biviano,et al.  Cardiac Arrhythmias in COVID-19 Infection , 2020, Circulation. Arrhythmia and electrophysiology.

[7]  P. Ravaud,et al.  Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data , 2020, BMJ.

[8]  J. Qu,et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.

[9]  Abhimanyu Beri,et al.  Cardiac injury, arrhythmia, and sudden death in a COVID-19 patient , 2020, HeartRhythm Case Reports.

[10]  Graham Peigh,et al.  Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series , 2020, European heart journal. Case reports.

[11]  S. Viskin,et al.  Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019 , 2020, Heart Rhythm.

[12]  D. Roden,et al.  Genetic susceptibility for COVID-19–associated sudden cardiac death in African Americans , 2020, Heart Rhythm.

[13]  N. Seecheran,et al.  Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection , 2020, Journal of investigative medicine high impact case reports.

[14]  M. Taha,et al.  Coronavirus Disease and New-Onset Atrial Fibrillation: Two Cases , 2020, Cureus.

[15]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[16]  Michael A. Spinelli,et al.  QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin , 2020, Heart Rhythm.

[17]  F. Crea,et al.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options , 2020, Cardiovascular research.

[18]  L. Epstein,et al.  Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection , 2020, Circulation. Arrhythmia and electrophysiology.

[19]  T. Quertermous,et al.  Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty , 2020, Current Cardiology Reports.

[20]  V. V. van Dijk,et al.  Chloroquine-induced QTc prolongation in COVID-19 patients , 2020, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[21]  C. Hedrich,et al.  COVID-19: Immunology and treatment options , 2020, Clinical Immunology.

[22]  C. Albert,et al.  Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring , 2020, medRxiv.

[23]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[24]  P. Brugada,et al.  The Known Into the Unknown , 2020, JACC: Case Reports.

[25]  J. Vincent,et al.  Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base , 2020, The Lancet Respiratory Medicine.

[26]  D. Roden,et al.  Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment , 2020, Heart Rhythm.

[27]  Q. Bassat,et al.  Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) , 2020, medRxiv.

[28]  A. Nabar,et al.  Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society , 2020, Indian Pacing and Electrophysiology Journal.

[29]  J. Healey,et al.  Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society , 2020, Canadian Journal of Cardiology.

[30]  E. Botelho-Nevers,et al.  Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  P. Noseworthy,et al.  Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) , 2020, Mayo Clinic Proceedings.

[32]  L. Epstein,et al.  Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin , 2020, HeartRhythm Case Reports.

[33]  C. Delaugerre,et al.  No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.

[34]  Giuseppe Citerio,et al.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) , 2020, Intensive Care Medicine.

[35]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[36]  Chang Hu,et al.  Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, medRxiv.

[37]  Alexis Jacquier,et al.  Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.

[38]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[39]  Chang Hu,et al.  Clinical Features and Treatment of 221 Patients with COVID-19 in Wuhan, China , 2020 .

[40]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[41]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[42]  N. Pandis,et al.  CONSORT 2010 statement: extension checklist for reporting within person randomised trials , 2017, British Medical Journal.

[43]  Z. Memish,et al.  Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia , 2014, International Journal of Infectious Diseases.

[44]  J. Guo,et al.  Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. , 2014, American health & drug benefits.

[45]  Noha H Farag,et al.  Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus: A Serologic, Epidemiologic, and Clinical Description , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  R. Kovacs,et al.  Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients , 2013, Circulation. Cardiovascular quality and outcomes.

[47]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[48]  J. Penninger,et al.  SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS , 2009, European journal of clinical investigation.

[49]  J. Sung,et al.  Cardiovascular complications of severe acute respiratory syndrome , 2006, Postgraduate Medical Journal.

[50]  Don C Des Jarlais,et al.  Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. , 2004, American journal of public health.

[51]  P. Hawkey,et al.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.

[52]  P. Brugada,et al.  The Known into the Unknown: Brugada syndrome and COVID-19 , 2020 .